Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice

Background: The non-homogenous distribution of antibody-drug conjugates (ADCs) within solid tumors is a major limiting factor for their wide clinical application. Nanobodies have been shown to rapidly penetrate into xenografts, achieving more homogeneous tumor targeting. However, their rapid renal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xenaki, Katerina T, Dorresteijn, Bram, Muns, Joey A, Adamzek, Kevin, Doulkeridou, Sofia, Houthoff, HendrikJan, Oliveira, Sabrina, van Bergen en Henegouwen, Paul MP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039960/
https://www.ncbi.nlm.nih.gov/pubmed/33859761
http://dx.doi.org/10.7150/thno.57510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039960/
https://www.ncbi.nlm.nih.gov/pubmed/33859761
http://dx.doi.org/10.7150/thno.57510

Ejemplares similares